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Abstract 
Purpose: To evaluate the efficiency of the UCA1 test as a diagnostic tool for the detection of bladder cancer.
Methods: Between October 2009 and December 2011 the UCA1 test was performed on collected urine samples 
from 162 patients divided into screening and follow-up groups, based on the absence or presence of prior bladder 
cancer. The test performance was then evaluated in each group and compared to cystoscopy and urinary cytology.
Results: The overall sensitivity, specificity and positive and negative predictive values for the UCA1 test were 70, 70.7, 
75.6 and 64.5%, respectively. We observed no difference in performance for tumours of higher grade or stage, but 
sensitivity was increased in the screening population compared to patients under follow-up (83.9 vs. 59%). The UCA1 
test successfully detected all 7 cases of isolated carcinoma in situ and was more sensitive in this particular setting than 
cystoscopy or urinary cytology.
Conclusion: The efficiency of the UCA1 test for the detection of primary and recurring bladder cancer in our study 
was lower than previously reported. We confirmed the role of UCA1 as a possible adjunct to cystoscopy and cytology 
when a primary bladder cancer is suspected, but its role in the follow-up of recurring tumours remains limited. Further 
studies are needed to investigate the role of the UCA1 test in the early detection of carcinoma in situ lesions.
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Background
Bladder cancer (BC) is the second most common urologic 
cancer. Although the majority of cases are diagnosed at 
early stages, up to 50% of tumours recur and 15–40% 
grow into muscle invasive disease (Amin et  al. 2015). 
According to current guidelines, the diagnostic stand-
ard for BC is cystoscopy, often combined with urinary 
cytology (Kamat et  al. 2013). This is also the approach 
used to follow-up patients with a history of BC. Though 
photodynamic diagnosis has improved the sensitivity of 
white cystoscopy for carcinoma in situ (CIS) lesions, both 
procedures remain invasive, time-consuming and costly, 
therefore making BC one of the most expensive malig-
nancies to monitor and treat (Isfoss 2011; Van Rhijn et al. 
2009). Cytology is a non-invasive test often performed on 
voided urine, with high specificity (96%) but low sensi-
tivity (44%), particularly for low-grade tumours (Kamat 
et  al. 2013). Several urine markers have been studied 
to help diagnose BC, and thereby decrease the need for 
cystoscopy as well as make following-up bladder can-
cer patients more cost-effective. To date, the Food and 
Drug Administration has approved six urine biomark-
ers for BC detection (Kamat et al. 2013; Tilki et al. 2011). 
Most markers have shown better sensitivity compared to 
cytology; however, their specificity remains lower (Tilki 
et al. 2011). None of those markers are currently recom-
mended as standard diagnostic tools in routine urology 
(Kamat et al. 2013; Tilki et al. 2011).
Urothelial carcinoma associated 1 (UCA1) was 
recently identified as a non-coding RNA upregulated in 
BC compared to normal bladder tissues, and is thought 
to be involved in embryogenesis and in BC progression 
(Wang et al. 2006, 2008, 2012). Overexpression of UCA1 
in the BLS-211 BC cell line significantly enhanced the 
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tumorigenicity, invasion potential and drug resistance, 
both in vitro and in vivo (Wang et al. 2008). Yang et al. 
showed that UCA1 stimulates cell proliferation via the 
p300 coactivator CREB, through a PI3K-AKT dependent 
pathway (Yang et al. 2012). UCA1 was also identified as 
a very sensitive and specific urine marker of BC (Wang 
et  al. 2006; Zhang et  al. 2012; Srivastava et  al. 2014). A 
recent study yielded a sensitivity of 79.49% and a speci-
ficity of 79.73%, suggesting that the UCA1 test could be 
used as an adjunct to cytology in early diagnosis of pri-
mary urinary BC (Srivastava et al. 2014). Those promising 
results motivated us to study the UCA1 test in an inde-
pendent cohort, with a view to validating UCA1 as a reli-
able biomarker for BC detection. Instead of using fresh 
urine samples stored on ice, as previously described, we 
developed the UCA1 test on fixed urine samples in order 
to facilitate its use in daily practice (Wang et  al. 2006). 
The test has been accredited (BELAC, ISO15189) since 
September 2009. The present work aims to report our 
experience regarding the clinical value of the UCA1 test 
when compared to routine diagnostic methods.
Methods
Patient selection
Freshly voided urine samples were obtained from 162 
patients between October 2009 and December 2012 at 
Erasme University Hospital, after approval by the local 
Ethical Committee (Ref: P2010/338). Patients were 
included in the study if they were (1) evaluated for sus-
pected primary BC, (2) under surveillance for BC or (3) 
followed for other urological conditions. The clinical 
data collected for each patient include age, prior medi-
cal history and treatment, symptoms, cystoscopic and/
or imaging findings, and follow-up through August 2014 
(Table 1). All BC diagnoses were confirmed by histology, 
except for one patient. This person’s histological confir-
mation was forgone due to advanced age, despite a visible 
bladder tumour at both cystoscopy and CT scan, as well 
as malignant urothelial cells identified by cytology. White 
cystoscopy was performed for all patients and regarded 
as positive in cases involving apparent papillary or flat 
lesions and considered negative if findings were normal.
Urine and tissue samples
Urine samples were collected in a tube containing 25 ml 
of the fixative solution Saccomanno™ (Prosan, Merelbeke, 
Belgium) and were delivered to the laboratory within 
24 h. From these samples, 50 ml was used to conduct rou-
tine cytology. All cytological diagnoses were reviewed by 
a uropathologist (SR). Cytology was categorized as posi-
tive if cancer cells or cells with atypical changes suggest-
ing malignancy were found, and as negative if normal cells 
or cells with inflammatory atypical changes were found.
Table 1 Patients demographics and baseline features









 Age (median (range)) 68 (32–90) 70 (35–90)
 Hematuria 48 60.8% 5 6% p < 0.00001
 Urinary tract infection 8 10.1% 1 1.2% p = 0.01
 Benign prostatic  
hyperplasia
18 22.8% 6 7.2% p = 0.004
 Renal transplant 10 12.7% 5 6% p = 0.1
 Lithiasis 5 6.3% 1 1.2% p = 0.09
 Hydronephrosis 7 8.9% 2 2.4% p = 0.07
 LUTS 12 15.2% 1 1.2% p = 0.0009
 Schistozomiasis 2 2.5% 0 0% p = 0.24
 Aristocholic acid  
nephropathy
5 6.3% 5 6% p = 1
 Other malignancies 14 17.7% 15 18.1% p = 1
UCA1 test p = 0.04
 Positive 43 54.4% 33 39.8%
 Negative 36 45.6% 50 60.2%
Cytology p = 0.09
 Positive 21 26.6% 14 16.9%
 Negative 49 62% 59 71.1%
 Unsatisfactory 9 11.4% 10 12%
Cystoscopy p = 0.56
 Positive 31 39.2% 36 43.4%
 Negative 39 49.4% 45 54.2%
 Not performed 9 11.4% 2 2.4%
Histology p = 0.56
 Benign 12 15.2% 15 18.1%
 Malignant 30 38% 39 47%
  Urothelial  
carcinoma
27 38
  Squamous  
carcinoma
2 0
  Adenocarcinoma 0 1
  Small cell carcinoma 1 0
 Not performed 37 46.8% 29 34.9%
 Stage
  pTis 1 1.3% 6 7.2%
  pTa 6 7.6% 15 18%
  pT1 9 11.8% 6 7.2%
  pT2 9 11.8% 8 9.6%
  pT3 4 5.1% 1 1.2%
  pT4 1 1.3% 3 3.6%
 Grade
  PUNLMP – –
  Low grade 7 8.9% 16 19.3%
  High grade 19 24% 16 19.3%
  CIS 1 1.3% 6 7.2%
  Not available 3 3.8% –
Page 3 of 6Milowich et al. SpringerPlus  (2015) 4:349 
The remaining urine volume was centrifuged at 
3,000 rpm for 30 min and rinsed with PBS. The resulting 
pellets were suspended in RNAlater™ solution (Qiagen, 
Venlo, Netherlands) and stored at 4°C. RNA extrac-
tion was conducted using an RNeasy Mini kit (Qia-
gen) following the manufacturer’s recommendations. 
After checking the RNA quality and purity (NanoDrop 
2000, Thermo Scientific, Aalst, Belgium), 50 ng of RNA 
extracts were submitted to reverse transcription using 
the Sensiscript Reverse Transcription Kit (Qiagen) and 
oligo(dT) primers (Invitrogen, Gent, Belgium). Amplifi-
cation was performed using UCA1 specific primers (For-
ward: 5′-GGGACTCCTTCGTGAGACC-3′ and Reverse: 
5′-AGAGGAACGGATGAAGCCTG-3′). The Tata box 
binding protein (TBP) was used as a housekeeping gene 
(Forward: 5′-GGCACCACTCCACTGTATC-3′ and 
Reverse: 5′-AATCAGTGCCGTGGTTCGT-3′). For both 
PCR reactions, 40 cycles were run (Thermocycler T3, 
94°C for 45  s, 57°C for 1  min, 72°C for 30  s). The PCR 
product was then resolved on agarose gels. Satisfactory 
tests were categorized using a three-tier score (negative, 
low or high UCA1 gene expression). The test was consid-
ered positive if the UCA1 gene was highly expressed, and 
negative if the UCA1 gene was weakly or not expressed 
at all in the sample analysed (Figure 1). Two independent 
investigators (MLM and SR), blinded to the clinical data, 
cystoscopy findings and cytological diagnoses, evaluated 
the result of each UCA1 test.
In 96 patients, tissue samples were retrieved by biopsy, 
transurethral resection of the bladder (TURB) or surgi-
cal procedures. The histopathological diagnoses were 
reviewed by a uropathologist (SR).
Data analysis
Patients were divided into screening and follow-up 
groups, based on absence or presence of prior BC. 
Patients were considered disease-free if the workup was 
negative and no evidence of BC was found in the six fol-
lowing months. Patients with insufficient follow-up were 
excluded from the study. We evaluated the sensitivity, 
specificity, positive and negative predictive values of the 
UCA1 test in both patient groups compared to cystos-
copy and cytology.
Results
Among the 162 patients included in this study, 79 had 
no prior history of BC and 83 were part of the follow-
up cohort. For each of these two groups, the breakdown 
between patients in terms of clinical features, cytology, 
cystoscopy and UCA1 test results is shown in Table  1. 
In all, 69 diagnoses of BC were made, of which 30 were 
primary BCs and 39 recurrent cases. Most cases (n = 65) 
were diagnosed as urothelial carcinomas, though two 
cases of pure squamous cell carcinoma and single cases 
of primary bladder adenocarcinoma and small cell car-
cinoma were also encountered. For 66 patients, no his-
tological material was available and 65 of these patients 
were considered disease-free, as there was no suspicion 
of malignancy at the initial workup or during a follow-up 
of at least 6  months either. One patient was diagnosed 
with a locally advanced bladder tumour on imaging find-
ings and malignant urothelial cells were identified by 
cytology, but no further investigations were carried out 
due to the patient’s age and performance status.
Table 2 illustrates the sensitivities, specificities, positive 
and negative predictive values of urinary cytology, cys-
toscopy and the UCA1 test designed to detect BC in the 
screening and follow-up groups.
The overall sensitivities of cytology, cystoscopy and the 
UCA1 test were 50.8, 79.1 and 70%. The sensitivity of the 
UCA1 test was higher in the screening group compared 
to the follow-up group, (83.9 vs. 59%), yielding a negative 
predictive value of 86.1 and 68% respectively. Cystoscopy 
and urinary cytology were also less sensitive for detect-
ing recurrences, with cystoscopy remaining the most 
a Some patients present multiple clinical features.
Table 1 continued









  Single tumours 16 20.2% 20 24.1%
  Multiple tumours 10 12.6% 11 13.6%
  Not available 4 5.1% 1 1.2%
Figure 1 Expression of the UCA1 gene in urinary samples deter-
mined by semi-quantitative RT-PCR. This figure illustrates the 
expression of the UCA1 gene in urinary samples determined by semi-
quantitative RT-PCR. Lanes 1 and 2 were negative controls for PCR (1) 
and reverse transcription (2). Lane 11 was the positive control consist-
ing of RNA extracted from frozen bladder cancer tissue. TBP was used 
as an internal control. Cases (4) and (10) were considered unsatisfac-
tory for evaluation because no TBP expression was detected. Cases 
(3) and (6) had no UCA1 expression, cases (5) and (8) had weak UCA1 
expression and cases (7) and (9) had strong UCA1 expression.
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efficient procedure (90 and 70.3% sensitivity for screening 
and follow-up), while urinary cytology detected 71.4% of 
primary BCs and only 34.3% of recurrences. Conversely, 
the UCA1 test proved to be more specific in the follow-
up group as compared to the screening group (77.3 vs. 
64.6%), yielding a positive predictive value of 64.5% over-
all. The specificity of cystoscopy in the follow-up group 
was equivalent (77.3%) to the UCA1 test, but both cys-
toscopy and cytology were more specific than the UCA1 
test in the screening setting.
Table  3 illustrates the number and percentages of 
patients reported as positive by cytology, cystoscopy 
and the UCA1 test according to grade and stage. Cytol-
ogy was more often positive in BC of higher grade (70.6% 
in high-grade vs. 11.8% in low-grade tumours) and stage 
(13.3% for pTa, 60% for pT1 and 71.4% for ≥pT2 tumours). 
Conversely, the result of the UCA1 test did not vary sig-
nificantly between low-grade and high-grade tumours 
(60.9 vs. 71.4%) and did not correlate with stage (57.1% 
for pTa tumours vs. 93.3% for pT1 tumours; 59.1% for 
≥pT2 tumours). Cystoscopy remained the most efficient 
diagnostic tool, irrespective of grade and stage, except for 
CIS. Interestingly, the UCA1 test successfully detected all 
seven cases of CIS and was more sensitive than cytology 
or cystoscopy in this setting. The UCA1 test was also pos-
itive in one of two cases of squamous cell carcinoma and 
small cell carcinoma; however, the only case of primary 
bladder adenocarcinoma did not express UCA1.
Discussion
Since its first description in 2006, several studies have 
confirmed UCA1 to be a biomarker for urothelial carci-
noma and studied its expression in other cancers, includ-
ing colorectal and breast cancers (Wang et  al. 2006, 
2008, 2012; Yang et al. 2012; Zhang et al. 2012; Srivastava 
et  al. 2014; Han et  al. 2014; Huang et  al. 2014). Moreo-
ver, long non-coding RNAs, like UCA1, are increasingly 
thought to play a pivotal role in cancer development 
and progression (Shi et  al. 2013; Li and Chen 2013). To 
date, only three studies have addressed the role of UCA1 
as a urinary marker. BC is the second most common 
urologic malignancy, yet it is one of the most challeng-
ing to treat due to significant tumour heterogeneity and 
potential life-long follow-up, which includes time-con-
suming and invasive procedures. The implementation of 
a urinary biomarker in clinical practice could allow for 
longer intervals between cystoscopies and a less invasive 
follow-up, but should not come at the expense of lower 
sensitivity.
Table 2 Sensitivity of diagnostic methods for bladder cancer (including carcinoma in situ) according to grade and stage
a  7 cases were unsatisfactory for interpretation (6 low grade and 1 high grade tumors); b 6 cases were unsatisfactory for interpretation; c 1 case was unsatisfactory for 
interpretation; d cystoscopy was not performed in 2 cases (1 high grade tumors and 1 CIS); e cystoscopy was not performed in 1 case.
UCA1 test Cytology Cystoscopy
Overall n = 69
Urothelial carcinoma n = 65 46/65 70.8% 29/58a 50% 51/63d 81%
 Low-grade n = 23 14/23 60.9% 2/17 11.8% 19/23 82.6%
 High-grade n = 35 25/35 71.4% 24/34 70.6% 29/34 85.3%
 CIS n = 7 7/7 100% 3/7 42.9% 3/6 50%
Squamous cell carcinoma n = 2 1/2 1/2 1/2
Adenocarcinoma n = 1 0/1 0/1 0/1
Small cell carcinoma n = 1 1/1 1/1 1/1
 pTa n = 21 12/21 57.1% 2/15b 13.3% 18/21 85.7%
 pT1 n = 15 14/15 93.3% 9/15 60% 13/15 86.7%
 ≥pT2 n = 26 15/26 57.7% 17/25c 68% 19/25e 76%
Table 3 Diagnostic value of  the UCA1 test, urinary cytol-
ogy and cystoscopy for the detection of bladder cancer
UCA1 test Cytology Cystoscopy
Screening
 Sensitivity 83.9% 71.4% 90%
 Specificity 64.6% 97.6% 90%
 Negative predictive value 86.1% 83.7% 92.3%
 Positive predictive value 60.5% 95.2% 87.1
Follow-up
 Sensitivity 59% 34.3% 70.3%
 Specificity 77.3% 94.7% 77.3%
 Negative predictive value 68% 61% 75.6%
 Positive predictive value 69.7% 85.7% 72.2%
Overall
 Sensitivity 70% 50.8% 79.1%
 Specificity 70.7% 96.3% 83.3%
 Negative predictive value 75.6% 71.3% 83.3%
 Positive predictive value 64.5% 91.4% 79.1%
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In previous studies, the sensitivity of the UCA1 marker 
ranged from 79.5 to 88.5%. With an overall sensitivity of 
70%, the ability of the UCA1 test to detect BC was sig-
nificantly lower in our series. However, when limited to 
the screening group, the UCA1 test yielded a sensitivity 
of 83.9%, which is comparable to reported results. Two 
of the previous studies did not detail the patients’ history 
of BC, but Srivastava et  al. reported a significant differ-
ence in expression of UCA1 in recurrent tumours com-
pared to primary tumours (p  <  0.001), emphasizing the 
necessity to analyse patients with recurrent BC separately 
when evaluating a novel biomarker (Srivastava et  al. 
2014). The positive and negative predictive values of the 
UCA1 test were lower than previously reported (64.5 and 
75.6% respectively), despite a relatively high prevalence 
of bladder cancer in our patients population (Srivastava 
et al. 2014).
The overall specificity of the UCA1 test was 70.7%, 
ranging lower than the previously published results 
(79.7–92.3%). In our study, 27 patients with a posi-
tive UCA1 test had no evidence of disease for at least 
6 months and up to 53 months of follow-up. Neverthe-
less, late recurrences have been reported, which provide 
reasonable explanations for false positive results with 
other urinary markers, particularly FISH-based markers 
(Kamat et al. 2014 Oct). Anticipatory false-positive find-
ings cannot be excluded at this stage and overexpression 
of UCA1 may be due to its expression in early precursor 
lesions that remain clinically undetectable. This hypoth-
esis is supported by the detection of UCA1 in all seven 
cases of CIS and, additionally, in two cases of urothelial 
dysplasia (data not shown). Though four patients with 
false-positive tests were under surveillance for BC due to 
exposure to aristocholic acid, and one patient had been 
diagnosed with chronic schistosomiasis—two condi-
tions associated with urothelial carcinogenic ability and 
urothelial dysplasia –, we did not find any association 
between particular clinical features and a false-positive 
test (Botelho et  al. 2011; Lemy et  al. 2008). Our study 
included only seven patients with CIS, but it is interest-
ing to note that the UCA1 test detected three additional 
cases compared to cystoscopy. However, in order to 
evaluate the efficiency of the UCA1 test in flat urothelial 
lesions, further studies on larger cohorts are necessary.
Contrary to previous reports where UCA1 has emerged 
as a particularly sensitive marker for superficial high-
grade tumours, we did not find any significant difference 
in terms of sensitivity when the UCA1 test was analysed 
according to grade. Although the UCA1 test was particu-
larly efficient in detecting pT1 tumours, the sensitivity for 
both non-invasive and muscle-invasive tumours was 57%.
UCA1 expression was increased in various urothelial 
neoplastic lesions, including urothelial dysplasia, CIS 
and papillary low-grade and high-grade urothelial car-
cinomas—each associated with different morphology, 
pathogenesis and prognostic implications. Increased 
expression of UCA1 has been associated with tumour 
proliferation, migration and invasion, though the exact 
mechanisms are yet to be elucidated. Recently, Wang 
et  al. reported that UCA1 promotes cell growth by 
downregulating the cell cycle inhibitor p21 via BRG1, a 
chromatin remodelling factor with anti-tumour prop-
erties (Wang et  al. 2014). Furthermore, upregulated 
UCA1 has been shown to promote resistance to cispl-
atin-based chemotherapy in bladder cancer cells (Fan 
et al. 2014). Taken together, these findings indicate that 
UCA1 plays an important role in BC pathogenesis and 
progression, while its characterisation may provide new 
insights in early stages of BC development and, possibly, 
even new prognostic factors and therapeutic targets. It 
remains to be proven whether UCA1 is a suitable diag-
nostic urinary biomarker in BC and a useful contribu-
tion to already existing diagnostic procedures in daily 
urologic practice.
In conclusion, the efficiency of the UCA1 test for the 
diagnosis of BC in our study was lower than previously 
reported. Our results highlight the importance of testing 
novel urinary biomarkers in specific patient populations. 
The UCA1 test cannot replace cystoscopy for the evalua-
tion of patients with suspected primary BC or in the con-
text of a follow-up for bladder cancer. While it may aid in 
the detection of CIS, more extensive studies are needed 
to confirm these findings. Conversely, our results did 
not provide evidence that the UCA1 test is suitable for 
the follow-up of patients with previous BC, due to its low 
sensitivity in this population.
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